Related Experiment Videos
A cost-utility analysis of therapy for amblyopia
Jaime H Membreno1, Melissa M Brown, Gary C Brown
1Center for Evidence-Based Health Care Economics, Flourtown, Pennsylvania 19031, USA.
Ophthalmology
|December 6, 2002
Summary
Amblyopia therapy is highly cost-effective, costing $2281 per quality-adjusted life-year gained. This finding supports its value for healthcare policy decisions.
Area of Science:
- Ophthalmology
- Health Economics
- Public Health
Background:
- Amblyopia, or "lazy eye," is a common cause of reduced vision in children.
- Effective treatment is crucial to prevent long-term visual impairment.
Purpose of the Study:
- To evaluate the cost-effectiveness of amblyopia therapies.
- To inform healthcare policy regarding amblyopia treatment.
Main Methods:
- A cost-utility analysis was conducted from a third-party insurer perspective.
- Decision analysis incorporated literature data and patient utility values.
- Treatment followed American Academy of Ophthalmology guidelines.
Main Results:
- The cost per quality-adjusted life-year (QALY) gained was $2281.
- Sensitivity analysis showed a range of $2053 to $2509 per QALY.
- A 3% discount rate was applied to costs and outcomes.
Conclusions:
- Amblyopia therapy demonstrates significant cost-effectiveness compared to other healthcare interventions.
- This data is vital for healthcare policymakers.
- Early and effective treatment of amblyopia offers substantial value.